Polycystic Ovary Syndrome (PCOS) Treatment Market Size to Exceed USD 1,666.1 Mn by 2032

The Polycystic Ovary Syndrome (PCOS) Treatment Market, estimated at USD 1,195.2 Mn in 2025, is expected to exhibit a CAGR of 4.86% and reach USD 1,666.1 Mn by 2032.

The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.

The key players in the market are focusing on adoption of inorganic growth strategies, such as acquisitions and collaborations in order to strengthen their market presence in the global polycystic ovary syndrome (PCOS) treatment market and this is expected to drive the market growth over the forecast period. For instance, in August 2025, Bayer AG, a pharmaceutical company, and KaNDy Therapeutics Ltd, a U.K.-based clinical-stage biotech company, announced that Bayer will acquire KaNDy Therapeutics Ltd to expand its drug development pipeline in the field of women's health. As KaNDy Therapeutics Ltd. recently completed and published the results of the Phase IIb dose-ranging study for its investigational compound NT-814, a potential first-in-class, once-daily oral neurokinin 1,3 receptor antagonist, which showed positive results for the treatment of moderate to severe vasomotor symptoms due to menopause.

Global Polycystic Ovary Syndrome (PCOS) Treatment Market– Impact of Coronavirus (COVID-19) Pandemic

The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), that first appeared in Wuhan (province of Hubei, China) in the last months of 2025 as "coronavirus disease 2025" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.

The COVID-19 affected the economy in three main ways:  by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others faced problems with regards to the transportation of drugs from one place to another.

The COVID-19 had a positive impact on the global Polycystic Ovary Syndrome (PCOS) Treatment market, owing to its diagnostic application in the COVID-19-pandemic. For instance, according to research study published by European Journal of Endocrinology in May 2025, resulted that Women with PCOS are at increased risk of contracting COVID-19 and should be strongly encouraged to adhere to infection control measures during the COVID-19 pandemic.

Global Polycystic Ovary Syndrome (PCOS) Treatment Market: Key Developments

On January 04, 2025, Celmatix Inc., a biotechnology company, announced that it has reached a fourth milestone in its five-year multi-target alliance with Evotec for the Polycystic Ovary Syndrome (PCOS) Drug Program. The milestone was triggered by Evotec and Bayer AG advancing the identification of a second drug program focused on a novel drug target identified by Celmatix.

In October 2025, Bharat Serums and Vaccines Limited, a pharmaceutical company had launched an awareness campaign on various aspects of PCOS through its Start Your Joy microsite during Polycystic Ovary Syndrome (PCOS) Awareness Month.

Browse 24 Market Data Tables and 28 Figures spread through 192 Pages and in-depth TOC on “Global Polycystic Ovary Syndrome (PCOS) Treatment Market”- Forecast to 2032 by Drug Class (Oral contraceptives, Insulin Sensitizing Agents, Anti-Depressants, Ornithine Decarboxylase Inhibitors, Aromatase Inhibitors & SERMs and Diuretics), by End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Clinical Research, and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/polycystic-ovarian-syndrome-treatment-market-1589

Key Takeaways of the Global Polycystic Ovary Syndrome (PCOS) Treatment Market:

• The global Polycystic Ovary Syndrome (PCOS) Treatment market is expected to exhibit a CAGR of 4.86% during the forecast period. Increasing number of Polycystic Ovary Syndrome (PCOS) in women is expected to drive the segment growth over the forecast period. For instance, according to research study published by Chengdu University of Traditional Chinese Medicine in March 2025 stated that, to comprehensively estimate the prevalence of polycystic ovary syndrome (PCOS) in Chinese women and provide guidance on how to prevent PCOS. The research study resulted that, total of 69 studies were involved in, including 154,599 participants, 12,845 patients developed PCOS. The prevalence of PCOS was 10.01%
• Among drug class, oral contraceptives segment is estimated to hold a dominant position in the global polycystic ovary syndrome (PCOS) treatment market over the forecast period, owing to increasing research and development for oral contraceptives and its benefits For instance, in October 2025, a research study were conducted by University of Birmingham, resulted that birth control pills can reduce the risk of type 2 diabetes in women with polycystic ovary syndrome (PCOS) by more than a quarter.
• Among region, North America is expected to be the dominant region in the global Polycystic Ovary Syndrome (PCOS) Treatment market, owing to increasing research and development activities by market players in the market to for the new drug development, which is expected to drive the segment growth over the forecast period. For instance, in January 2025, Abbvie Inc., an American pharmaceutical company had an active clinical trial in the pipeline with the molecule Elagolix in January 2025, which is being evaluated for its safety and efficacy in women with polycystic ovary syndrome. The company is currently conducting a Phase 2 multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of Elagolix in women with polycystic ovary syndrome (PCOS).
• Major players operating in the global Polycystic Ovary Syndrome (PCOS) Treatment market include Key companies covered as a part of this study Sanofi S.A., Amneal Pharmaceuticals, Inc., Laurus Labs Limited, Zydus Pharmaceuticals, Inc., Prasco Laboratories, Dr. Reddy's Laboratories, Cadila Pharmaceuticals, Novartis International AG, Concordia Pharmaceuticals Inc., Evotec SE, Covis Pharmaceuticals, Inc., Cardinal Health, Aphena Pharma Solutions Tennessee, Inc., Mylan N.V., McKesson Corporation, Teva Pharmaceutical Industries Ltd, Lupin Pharmaceutical and Sun Pharmaceutical Industries Ltd., Bayer AG, and other prominent players